Almotriptan hydrochloride

Almotriptan (0.01-3000 μg/kg; intravenous/intradermal administration; single dose) hydrochloride increases carotid vascular resistance in anesthetized cats, with efficacy and potency comparable to those of Sumatriptan; it elevates resistance by 100% at an intravenous dose of 9 μg/kg and exerts effects via the 5-HT₁ receptor^[2].
Almotriptan (0-1 mg/kg; intravenous injection; single dose; maximum 0.3 mg/kg; intravenous injection; single dose; 30 μg/min; intracoronary infusion; 1 h) hydrochloride increases carotid vascular resistance in beagle dogs, and exhibits better carotid-femoral artery selectivity than Sumatriptan. At the tested doses, this agent has favorable cardiovascular safety, with no cardiac inhibitory effect or QTc interval change^[2].
Almotriptan (10 mg/kg; subcutaneous injection; single dose) hydrochloride inhibits trigeminal ganglion-induced meningeal vascular extravasation in anesthetized guinea pigs, and at a subcutaneous dose of 10 mg/kg, it causes no hypothermia or bronchospasm in conscious guinea pigs^[2].
Almotriptan (oral administration; single dose) hydrochloride does not alter cardiovascular parameters or diuretic effects in normotensive Wistar rats at the tested oral doses^[2].
Almotriptan (1-3 mg/kg; subcutaneous injection; single administration) hydrochloride exerts no cardiovascular effects at the dose of 1 mg/kg s.c. in conscious cynomolgus monkeys, while the 3 mg/kg s.c. dose only induces mild, transient effects without electrocardiogram changes^[2].
Almotriptan (up to 300 mg/kg; p.o.; single administration) hydrochloride shows no central nervous system-related behavioral or motor function effects in mice at oral doses up to 300 mg/kg^[2].
Almotriptan hydrochloride slightly alleviates apomorphine (HY-12723)-induced vomiting responses in dogs^[2].